Company logo

JAGX - Jaguar Health, Inc.

NASDAQ -> Healthcare -> Biotechnology
San Francisco, United States
Type: Equity

JAGX price evolution
JAGX
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Jan 2023
Current assets
Cash $3.23 $8.63 $14.37 $5.47
Short term investments
Net receivables $1.84 $1.56 $1.44 $2.47
Inventory $8.38 $8.26 $8.68 $7.02
Total current assets $22.06 $28.23 $32.36 $22.32
Long term investments
Property, plant & equipment $1.33 $1.47 $1.6 $1.7
Goodwill & intangible assets $20.97 $21.46 $21.95 $22.44
Total noncurrent assets $23.32 $23.95 $24.57 $25.13
Total investments
Total assets $45.38 $52.17 $56.93 $47.45
Current liabilities
Accounts payable $5.13 $4.66 $5.69 $5.81
Deferred revenue
Short long term debt $4.04 $14.32 $16.12 $16.37
Total current liabilities $12.46 $29 $31.1 $30.34
Long term debt $31.51 $17.34 $18.17 $17.74
Total noncurrent liabilities $31.51 $17.34 $18.17 $18.47
Total debt $35.54 $31.66 $34.3 $34.84
Total liabilities $43.96 $46.34 $49.27 $48.11
Shareholders' equity
Retained earnings -$299.08 -$291.3 -$279.15 -$266.95
Other shareholder equity -$0.8 -$0.72 -$0.88 -$0.68
Total shareholder equity $1.36 $5.64 $7.35 -$0.66
(in millions $) 31 Jan 2023 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $5.47 $17.05 $8.09 $3.88
Short term investments
Net receivables $2.47 $2.14 $4.56 $1.69
Inventory $7.02 $4.9 $2.78 $2.13
Total current assets $22.32 $28.43 $17.79 $9.52
Long term investments
Property, plant & equipment $1.7 $1.73 $0.68 $1.26
Goodwill & intangible assets $22.44 $22.65 $24.34 $26.02
Total noncurrent assets $25.13 $24.83 $25.05 $26.89
Total investments
Total assets $47.45 $53.27 $42.84 $36.41
Current liabilities
Accounts payable $5.81 $4.93 $4.76 $5.35
Deferred revenue
Short long term debt $16.37 $3.42 $3.79 $7.12
Total current liabilities $30.34 $15.47 $13.22 $15.39
Long term debt $17.74 $25.94 $12.42 $0.45
Total noncurrent liabilities $18.47 $25.94 $12.42 $0.45
Total debt $34.84 $29.36 $16.21 $7.57
Total liabilities $48.11 $41.41 $25.64 $15.84
Shareholders' equity
Retained earnings -$266.95 -$219.49 -$166.9 -$133.09
Other shareholder equity -$0.68 $11.61
Total shareholder equity -$0.66 $11.61 $17.2 $10.67
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue $2.81 $2.68 $1.97 $3.26
Cost of revenue $0.51 $0.49 $0.34 $0.49
Gross Profit $2.3 $2.19 $1.63 $2.77
Operating activities
Research & development $6.08 $4.28 $4.78 $4.31
Selling, general & administrative $5 $6.01 $6.7 $4.74
Total operating expenses $11.16 $10.29 $11.47 $9.05
Operating income -$8.86 -$8.1 -$9.85 -$6.29
Income from continuing operations
EBIT -$7.28 -$8.7 -$10.02 -$4.66
Income tax expense
Interest expense $0.5 $3.45 $2.18 $2.63
Net income
Net income -$7.78 -$12.15 -$12.2 -$7.29
Income (for common shares) -$7.78 -$12.15 -$12.2 -$7.58
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $11.96 $4.33 $9.38 $5.78
Cost of revenue $2.02 $2.33 $3.28 $3.82
Gross Profit $9.94 $2 $6.11 $1.96
Operating activities
Research & development $17.65 $15.08 $6.41 $5.82
Selling, general & administrative $26.7 $26 $21 $20.44
Total operating expenses $44.35 $42.71 $32.75 $30.91
Operating income -$34.41 -$40.71 -$26.65 -$28.95
Income from continuing operations
EBIT -$34.73 -$44.18 -$31.02 -$32.8
Income tax expense $0.01
Interest expense $12.72 $8.42 $2.79 $5.73
Net income
Net income -$47.45 -$52.6 -$33.81 -$38.54
Income (for common shares) -$47.45 -$52.59 -$38.65 -$44.73
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income -$7.78 -$12.15 -$12.2 -$7.29
Operating activities
Depreciation $0.63 $0.62 $0.55 $0.6
Business acquisitions & disposals
Stock-based compensation $0.53 $0.53 $0.48 $0.4
Total cash flows from operations -$6.79 -$9.06 -$9.95 -$6.42
Investing activities
Capital expenditures -$1.6
Investments
Total cash flows from investing -$0.36
Financing activities
Dividends paid
Sale and purchase of stock $2.66 $1.55 $17.86 $2.68
Net borrowings -$0.06 -$0.29 -$1.04
Total cash flows from financing $1.41 $3.36 $18.81 $1.64
Effect of exchange rate -$0.02 -$0.04 $0.03 $0.05
Change in cash and equivalents -$5.4 -$5.74 $8.9 -$5.09
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$47.45 -$52.6 -$33.81 -$38.54
Operating activities
Depreciation $2.29 $1.81 $2.28 $1.93
Business acquisitions & disposals
Stock-based compensation $3.32 $3.97 $3.81 $3.13
Total cash flows from operations -$33.1 -$34.97 -$15.28 -$20.46
Investing activities
Capital expenditures -$1.68 -$0.01 -$0.01
Investments
Total cash flows from investing -$1.68 -$0.01 -$0.01
Financing activities
Dividends paid
Sale and purchase of stock $20.46 $35.62 $7.76 $6.63
Net borrowings $2.72 $8.11 $12.06 -$0.1
Total cash flows from financing $23.18 $43.94 $19.49 $21.77
Effect of exchange rate $0.02
Change in cash and equivalents -$11.58 $8.96 $4.21 $1.32
Fundamentals
Market cap $8.69M
Enterprise value $41.00M
Shares outstanding 24.82M
Revenue $10.72M
EBITDA -$28.25M
EBIT -$30.65M
Net Income -$39.42M
Revenue Q/Q -10.70%
Revenue Y/Y -0.51%
P/E ratio -0.22
EV/Sales 3.82
EV/EBITDA -1.45
EV/EBIT -1.34
P/S ratio 0.81
P/B ratio 4.03
Book/Share 0.09
Cash/Share 0.13
EPS -$1.59
ROA -78.09%
ROE -1.15K%
Debt/Equity -73.23
Net debt/EBITDA -1.44
Current ratio 1.77
Quick ratio 1.10